Author:
Huang Yuan,Yi Jie,Song Jing-jing,Du Li-jun,Li Xiao-meng,Cheng Lin-lin,Yan Song-xin,Li Hao-long,Liu Yong-mei,Zhan Hao-ting,Dou Ya-ling,Li Yong-zhe
Abstract
Abstract
Objective
The current study evaluated the diagnostic performance of serum (1,3)-beta-D Glucan (BDG) in differentiating PJP from P. jirovecii-colonization in HIV-uninfected patients with P. jirovecii PCR-positive results.
Methods
This was a single-center retrospective study between 2019 and 2021. The diagnosis of PJP was based on the following criteria: detection of P. jirovecii in sputum or BAL specimen by qPCR or microscopy; Meet at least two of the three criteria: (1) have respiratory symptoms of cough and/or dyspnea, hypoxia; (2) typical radiological picture findings; (3) receiving a complete PJP treatment. After exclusion, the participants were divided into derivation and validation cohorts. The derivation cohort defined the cut-off value of serum BDG. Then, it was verified using the validation cohort.
Results
Two hundred and thirteen HIV-uninfected patients were enrolled, with 159 PJP and 54 P. jirovecii-colonized patients. BDG had outstanding specificity, LR, and PPV for PJP in both the derivation (90.00%, 8.900, and 96.43%) and the validation (91.67%, 9.176, and 96.30%) cohorts at ≥ 117.7 pg/mL. However, it had lower sensitivity and NPV in the derivation cohort (89.01% and 72.97%), which was even lower in the validation cohort (76.47% and 57.89%). Of note, BDG ≥ 117.7 pg/mL has insufficient diagnostic efficacy for PJP in patients with lung cancer, interstitial lung disease (ILD) and nephrotic syndrome. And although lymphocytes, B cells, and CD4+ T cells in PJP patients were significantly lower than those in P. jirovecii-colonized patients, the number and proportion of peripheral blood lymphocytes did not affect the diagnostic efficacy of serum BDG.
Conclusions
Serum BDG ≥ 117.7 pg/mL could effectively distinguish P. jirovecii-colonization from infection in qPCR-positive HIV-uninfected patients with infectious diseases, solid tumors (excluding lung cancer), autoimmune or inflammatory disorders, and hematological malignancies. Of note, for patients with lung cancer, ILD, and nephrotic diseases, PJP should be cautiously excluded at BDG < 117.7 pg/mL.
Funder
National Key Research and Development Program of China
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference48 articles.
1. Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J et al. Clinical course, treatment and outcome of Pneumocystis Pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Critical care (London, England). 2018;22(1):307. Epub 2018/11/21. https://doi.org/10.1186/s13054-018-2221-8. PubMed PMID: 30454031; PubMed Central PMCID: PMCPMC6245758.
2. Salzer HJF, Schäfer G, Hoenigl M, Günther G, Hoffmann C, Kalsdorf B, et al. Clinical, diagnostic, and treatment disparities between HIV-Infected and Non-HIV-Infected immunocompromised patients with Pneumocystis Jirovecii Pneumonia. Respir Int Rev Thorac Dis. 2018;96(1):52–65. 10.1159/000487713. PubMed PMID: 29635251.
3. Fishman JA. Pneumocystis Jiroveci. Semin Respir Crit Care Med. 2020;41(1):141–57. https://doi.org/10.1055/s-0039-3399559. Epub 2020/01/31. PubMed PMID: 32000290.
4. Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect diseases: IJID : official publication Int Soc Infect Dis. 2016;46. https://doi.org/10.1016/j.ijid.2016.03.018. Epub 2016/03/30. :11 – 7.
5. van Halsema C, Johnson L, Baxter J, Douthwaite S, Clowes Y, Guiver M, et al. Short communication: diagnosis of Pneumocystis Jirovecii Pneumonia by detection of DNA in blood and Oropharyngeal Wash, compared with Sputum. AIDS Res Hum Retroviruses. 2016;32(5):463–6. https://doi.org/10.1089/aid.2015.0213. Epub 2016/01/08.